Biomimetic reassembled chylomicrons as novel association model for the prediction of lymphatic transportation of highly lipophilic drugs via the oral route

International Journal of Pharmaceutics

Volumn 483, Issue 1-2, 2015, Pages 69-76

  Lu, Yi ^a   Qiu, Yiting ^a   Qi, Jianping ^a   Feng, Meiqing ^a   Ju, Dianwen ^a   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chylomicrons; Lymphatic transportation; Molecular descriptor; Oral; Reassembled

Indexed keywords

APOLIPOPROTEIN; CHYLOMICRON; CINNARIZINE; CLOFIBRATE; FENOFIBRATE; GRISEOFULVIN; HALOFANTRINE; LONG CHAIN TRIACYLGLYCEROL; MEVINOLIN; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; PACLITAXEL; PHOSPHOLIPID; PRAVASTATIN; PROGESTERONE; SIMVASTATIN; TRIACYLGLYCEROL; BIOMIMETIC MATERIAL; DRUG;

ANIMAL EXPERIMENT; ARTICLE; DENSITY; DISPERSION; DRUG SOLUBILITY; DRUG TRANSPORT; HYDROGEN BOND; LIPOPHILICITY; MALE; MELTING POINT; NONHUMAN; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; RAT; SURFACE PROPERTY; SUSPENSION; THERMODYNAMICS; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; CHEMISTRY; ORAL DRUG ADMINISTRATION; REGRESSION ANALYSIS; SOLUBILITY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOMIMETIC MATERIALS; CHYLOMICRONS; LEAST-SQUARES ANALYSIS; MALE; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY;

EID: 84922987532     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.02.017     Document Type: Article

References (27)

1. Ali Khan, A., Mudassir, J., Mohtar, N., Darwis, Y., 2013. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int. J. Nanomed. 8, 2733-2744.
2. Attili-Qadri, S., Karra, N., Nemirovski, A., Schwob, O., Talmon, Y., Nassar, T., Benita, S., 2013. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc. Natl. Acad. Sci. U. S. A. 110, 17498-17503.
3. Caliph, S.M., Faassen, F.W., Porter, C.J., 2014. The influence of intestinal lymphatic transport on the systemic exposure and brain deposition of a novel highly lipophilic compound with structural similarity to cholesterol. J. Pharm. Pharmacol. 66, 1377-1387.
4. Charman, W.N.A., Stella, V.J., 1986. Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules. Int. J. Pharm. 34, 175-178.
5. Cuong, N.V., Hsieh, M.F., 2011. Molecular targeting of liposomal nano-particles to lymphatic system. Curr. Cancer Drug Tar. 11, 147-155.
6. Dierling, A.M., Cui, Z., 2005. Targeting primaquine into liver using chylomicron emulsions for potential vivax malaria therapy. Int. J. Pharm. 303, 143-152.
7. Dierling, A.M., Sloat, B.R., Cui, Z., 2006. Gadolinium incorporated reconstituted chylomicron emulsion for potential application in tumor neutron capture therapy. Eur. J. Pharm. Biopharm. 62, 275-281.
8. Gershkovich, P., Fanous, J., Qadri, B., Yacovan, A., Amselem, S., Hoffman, A., 2009. The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons. J. Pharm. Pharmacol. 61, 31-39.
9. Gershkovich, P., Hoffman, A., 2005. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 26, 394-404.
10. Han, S., Quach, T., Hu, L., Wahab, A., Charman, W.N., Stella, V.J., Trevaskis, N.L., Simpson, J.S., Porter, C.J., 2014. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. J. Control. Release 177, 1-10.
11. Hara, T., Tan, Y., Huang, L., 1997. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector. Proc. Natl. Acad. Sci. U. S. A. 94, 14547-14552.
12. Ho, K.Y., Ord, M., Dodou, K., 2008. Effect of drug-polymer binary mixtures on the in-vitro release of ibuprofen from transdermal drug-in-adhesive layers. Drug Discov. Ther. 2, 277-281.
13. Hussain, M.M., 2000. A proposed model for the assembly of chylomicrons. Atherosclerosis 148, 1-15.
14. Ke, G., Wang, L., Wang, P., Lu, W., Wang, S., Zhang, Q., Guo, H., 2005. In vitro transdermal permeation of lidocaine-dodecanol binary eutectic system. Yaoxue Xuebao 40, 764-768.
15. Luchoomun, J., Hussain, M.M., 1999. Assembly and secretion of chylomicrons by differentiated Caco-2 cells. Nascent triglycerides and preformed phospholipids are preferentially used for lipoprotein assembly. J. Biol. Chem. 274, 19565-19572.
16. Mu, H., Porsgaard, T., 2005. The metabolism of structured triacylglycerols. Prog. Lipid. Res. 44, 430-448.
17. Nankervis, R., Davis, S.S., Day, N.H., Shaw, P.N., 1996. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. Int. J. Pharm. 130, 57-64.
18. Porter, C.J., Trevaskis, N.L., Charman, W.N., 2007. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6, 231-248.
19. Rensen, P.C., de Vrueh, R.L., Kuiper, J., Bijsterbosch, M.K., Biessen, E.A., van Berkel, T.J., 2001. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv. Drug Deliv. Rev. 47, 251-276.
20. Rubas, W., Grass, G.M., 1991. Gastrointestinal lymphatic absorption of peptides and proteins. Adv. Drug Deliv. Rev. 7, 15-69.
21. Sato, K., Takahashi, T., Takahashi, Y., Shiono, H., Katoh, N., Akiba, Y.,1999. Preparation of chylomicrons and VLDL with monoacid-rich triacylglycerol and characterization of kinetic parameters in lipoprotein lipase-mediated hydrolysis in chickens. J. Nutr. 129, 126-131.
22. Singh, I., Swami, R., Khan, W., Sistla, R., 2014. Lymphatic system: a prospective area for advanced targeting of particulate drug carriers. Expert Opin. Drug Deliv. 11, 211-229.
23. Tang, T.T., Hu, X.B., Liao, D.H., Liu, X.Y., Xiang, D.X., 2013. Mechanisms of microemulsion enhancing the oral bioavailability of puerarin: comparison between oil-in-water and water-in-oil microemulsions using the single-pass intestinal perfusion method and a chylomicron flow blocking approach. Int. J. Nanomed. 8, 4415-4426.
24. Trevaskis, N.L., Charman, W.N., Porter, C.J., 2008. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv. Drug Deliv. Rev. 60, 702-716.
25. Trevaskis, N.L., Porter, C.J., Charman, W.N., 2006. An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat. Drug Metab. Dispos. 34, 729-733.
26. Wasan, K.M., 2002. The role of lymphatic transport in enhancing oral protein and peptide drug delivery. Drug Dev. Ind. Pharm. 28, 1047-1058.
27. Yanez, J.A., Wang, S.W., Knemeyer, I.W., Wirth, M.A., Alton, K.B., 2011. Intestinal lymphatic transport for drug delivery. Adv. Drug Deliv. Rev. 63, 923-942.